Evolution of the Average Target: Actinium Pharmaceuticals, Inc.

Evolution of the Target Price: Actinium Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Actinium Pharmaceuticals, Inc.

10324ba4e154141e9.kLUDa5sJ4WvijLvxdd_qOXxIYjLm9Vx6nxyMzV84Dco.5ttAGPdish-o2-GwGq7HWh8eMlbUxSwt2HvJ9BFeQKn-_jFdyUuqEZb29g~27e008f651cf50be9156dfc29bcaa208
24-08-08 B. Riley Downgrades Actinium Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $2 From $16 MT
24-08-07 B. Riley Downgrades Actinium Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $2 From $16 MT
24-05-14 Stephens Initiates Actinium Pharmaceuticals With Overweight Rating, $25 Price Target MT
24-03-19 Maxim Adjusts Actinium Pharmaceuticals' Price Target to $30 From $20, Maintains Buy Rating MT
23-12-11 B. Riley Adjusts Price Target on Actinium Pharmaceuticals to $16 From $20, Maintains Buy Rating MT
23-09-06 HSBC Starts Actinium Pharmaceuticals With Buy Rating, Price Target is $11.60 MT
23-08-15 HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $50 From $53, Keeps Buy Rating MT
23-03-02 B. Riley Raises Actinium Pharmaceuticals' Price Target to $20 From $18, Keeps Buy Rating MT
23-02-21 William Blair Downgrades Actinium Pharmaceuticals to Market Perform Rating From Outperform MT
22-10-31 HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $53 From $45, Maintains Buy Rating MT
22-10-31 B. Riley Raises Actinium Pharmaceuticals' PT to $18 From $16 After Positive Update of Phase 3 SIERRA Trial for Iomab-B, Keeps Buy Rating MT
22-09-08 Cantor Fitzgerald Initiates Actinium Pharmaceuticals at Overweight with $20 Price Target MT
22-08-25 B. Riley Securities Initiates Actinium Pharmaceuticals at Buy with $16 Price Target, Says Market Potential for Iomab-B Conditioning Underappreciated MT
22-04-13 Alliance Global Adjusts Price Target on Actinium Pharmaceuticals to $25 From $20, Maintains Buy Rating MT
21-08-03 Actinium Pharmaceuticals : HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $45 From $57, Maintains Buy Rating MT
21-04-01 Actinium Pharmaceuticals : HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $57 From $65, Maintains Buy Rating MT
20-11-05 Actinium Pharmaceuticals : Alliance Global Starts Actinium Pharmaceuticals at Buy With $25 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+236.54%
+14.63%
- - +45.47%
+61.67%
+5.3%
+29.48%
-18.91%
+18.92%
+9.52%
+3.31%
Average +40.59%
Weighted average by Cap. +23.12%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.040USD
Average target price
3.500USD
Spread / Average Target
+236.54%
High Price Target
5.000USD
Spread / Highest target
+380.77%
Low Price Target
2.000USD
Spread / Lowest Target
+92.31%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Stephens Inc.
Maxim
B. Riley
HSBC
HC Wainwright
William Blair & Co.
Cantor Fitzgerald
Alliance Global Partners
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.040USD
Average target price
3.500USD
Spread / Average Target
+236.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock
  4. Consensus Actinium Pharmaceuticals, Inc.